Insulin‐like growth factor‐1 stimulates regulatory Tcells and suppresses autoimmune disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The recent precipitous rise in autoimmune diseases is placing an increasing clinical and economic burden on health systems worldwide. Current therapies are only moderately efficacious, often coupled with adverse side effects. Here, we show that recombinant human insulin‐like growth factor‐1 (rh IGF ‐1) stimulates proliferation of both human and mouse regulatory T (Treg) cells in vitro and when delivered systemically via continuous minipump, it halts autoimmune disease progression in mouse models of type 1 diabetes ( STZ and NOD ) and multiple sclerosis ( EAE ) in vivo . rh IGF ‐1 administration increased Treg cells in affected tissues, maintaining their suppressive properties. Genetically, ablation of the IGF ‐1 receptor specifically on Treg cell populations abrogated the beneficial effects of rh IGF ‐1 administration on the progression of multiple sclerotic symptoms in the EAE model, establishing a direct effect of IGF ‐1 on Treg cell proliferation. These results establish systemically delivered rh IGF ‐1 as a specific, effective stimulator of Treg cell action, underscoring the clinical feasibility of manipulating natural tolerance mechanisms to suppress autoimmune disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetics, pathogenesis and clinical interventions in type 1 diabetes
Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature · doi:10.1038/nature08933 · Cited by 1,265 · cited 2×
“…hypoglycemic effects (LeRoith & Yakar, 2007) Since the homeostatic balance of Treg cells and auto-aggressive cells is critical in the development of autoimmune diabetes (Waid et al , 2008; Feuerer et al , 2009; Bluestone et al , 2010), we examined Treg cell numbers in peripheral blood and spleen.”
A Special Population of Regulatory T Cells Potentiates Muscle Repair
Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J. L., Cerletti, M., Jang, Y., Sefik, E., Tan, T. G., Wagers, A. J., Benoist, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.054 · Cited by 1,234 · cited 1×
“Given recent evidence of Treg (Burzyn et al , 2013), it is likely that local stimulation of Treg cell expansion by IGF-1 may contribute to its well-documented beneficial effects in tissue regeneration as well.”
THE NOD MOUSE: A Model of Immune Dysregulation
Anderson, M. S., & Bluestone, J. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115643 · Cited by 1,113 · cited 1×
“…subcutaneous implantation As the STZ model of T1D is caused by direct toxicity to pancreatic b -cells (Lenzen, 2008), we also tested an alternative, genetic model of T1D, the non-obese diabetic (NOD) mouse, which spontaneously develops autoimmune diabetes at 10 weeks (Anderson & Bluestone, 2005).”
Th17 and regulatory T cells in mediating and restraining inflammation
Littman, D. R., & Rudensky, A. Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.021 · Cited by 1,039
Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011 · cited 1×
“Whereas in humans, Foxp3 is not directly correlated with T-cell-mediated suppression (Wang et al, 2007), in the mouse, it is both necessary and sufficient for Treg development and function (Sakaguchi et al, 2007).”
BackgroundLe Roith, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702273360907 · Cited by 897
Stability of the Regulatory T Cell Lineage in Vivo
Rubtsov, Y. P., Niec, R. E., Josefowicz, S., Li, L., Darce, J., Mathis, D., Benoist, C., & Rudensky, A. Y. (2010) · Science · doi:10.1126/science.1191996 · Cited by 730 · cited 2×
“Among the genes belonging to this latter cluster is the IGF-1 receptor itself (Hill et al , 2007), which stimulates proliferation and maintenance of Treg cells in vivo (Rubtsov et al , 2010).”
The NOD mouse model of type 1 diabetes: As good as it gets?
Atkinson, M. A., & Leiter, E. H. (1999) · Nature Medicine · doi:10.1038/9442 · Cited by 588 · cited 1×
“Type-1 diabetes (T1D) is an autoimmune disease caused by T-cell-induced destruction of the insulin-producing b -cells of the pancreas (Atkinson & Leiter, 1999).”
Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1
LeRoith, D., & Yakar, S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0427 · Cited by 344 · cited 3×
“Notably, rhIGF-1 administration resulted in improved glucose homeostasis well beyond its direct hypoglycemic effects (LeRoith & Yakar, 2007) Since the homeostatic balance of Treg cells and auto-aggressive cells is critical in the development of autoimmune diabetes (Waid et al , 2008; Feuerer et al…”
Cited by
Functional characterization of the dural sinuses as a neuroimmune interface
Rustenhoven, J., Drieu, A., Mamuladze, T., de Lima, K. A., Dykstra, T., Wall, M., Papadopoulos, Z., Kanamori, M., Salvador, A. F., Baker, W., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.040 · Cited by 685
“…2019), KIT-ligand which promotes mast cell survival (Iemura et al., 1994), IGF1 which promotes Treg proliferation and suppression of autoimmunity (Bilbao et al., 2014), and CSF1 and CX3CL1 which are critical for dural macrophage survival and function (Van Hove et al., 2019) (Figure 4C), amongst…”
Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0030 · Cited by 319
“Because our FMD regimen is characterized by a severe restriction of both carbohydrates and proteins, the observed immunomodulatory effects could result from a combination of (i) carbohydrate restriction–induced reduction of blood glucose and CCL2, G-CSF, and GM-CSF levels, with consequently impaired monocyte mobilizat…”
BackgroundThe neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis
Hooten, K. G., Beers, D. R., Zhao, W., & Appel, S. H. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0329-3 · Cited by 275
Role of metabolism in neurodegenerative disorders
Procaccini, C., Santopaolo, M., Faicchia, D., Colamatteo, A., Formisano, L., de Candia, P., Galgani, M., De Rosa, V., & Matarese, G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.018 · Cited by 258
Metadata
- Authors
- Bilbao, D., Luciani, L., Johannesson, B., Piszczek, A., & Rosenthal, N.
- Venue
- EMBO Molecular Medicine
- Published
- 2014-11
- Volume
- 6
- Issue
- 11
- Pages
- 1423-1435
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2152780155
- Cited by
- 119
- References
- 9
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.